drugset / Trial / NCT01284621

Relative Bioavailability of Empagliflozin (BI 10773) and Ramipril Administered Together Compared to Empagliflozin (BI 10773) and Ramipril Alone in Healthy Volunteers

NCT01284621

Phase 1 Completed 23 enrolled Boehringer Ingelheim
RandomizedCrossoverOpen-labelTreatment

Summary

Primary objective:To investigate if BI 10773 affects the pharmacokinetics of ramipril and if ramipril affects the pharmacokinetics of BI 10773.

Timeline

Start
2011-01
Primary completion
2011-03
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Empagliflozin Small molecule 25 mg Oral
Subject Ramipril Small molecule 5 mg Oral

Indications

No indication recorded.